Form 4: Zoetis CFO Wetteny Reports Stock Transactions

Chief Financial Officer of Zoetis Inc., Joseph Wetteny, reports the vesting and disposal of restricted stock units.

Summary

• On February 8, 2025, Joseph Wetteny, the Chief Financial Officer of Zoetis Inc., reported transactions involving Zoetis Inc. common stock.
• These transactions included the vesting and settlement of restricted stock units (RSUs) into common stock.
• Specifically, 1,389 RSUs vested and were settled, resulting in the acquisition of 1,389 shares of common stock.
• Additionally, 2,936 RSUs vested and were settled, resulting in the acquisition of 2,936 shares of common stock.
• Wetteny also disposed of 476 shares at a price of $171.43 and 1,034 shares at a price of $171.43 to cover tax obligations.
• Following these transactions, Wetteny directly owns 18,967 shares of Zoetis Inc. common stock and 2,737 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document reports routine stock transactions related to executive compensation. There is no indication of significant positive or negative news.

Positives

• The vesting of RSUs indicates that performance milestones were likely met, which is a positive signal.

Negatives

• The disposal of shares to cover tax obligations, while common, could be interpreted as a slight negative, although it's a standard practice.

Risks

• There are no specific risks highlighted in this document, as it primarily details stock transactions.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. They are closely watched by investors as they can provide insights into management's confidence in the company's future prospects. However, routine vesting and sales for tax purposes are generally not considered significant indicators.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice among publicly traded companies like Zoetis, aligning with peers such as Elanco Animal Health and Merck Animal Health.
• The vesting schedules and terms of these equity grants are typically benchmarked against industry standards to attract and retain top talent.
• The sale of shares to cover tax obligations is a common practice among executives across various industries, including pharmaceuticals and animal health.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are part of standard executive compensation practices.

Key Dates